PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35197485-2	2022	We developed a recombinant spike protein vaccine (called NARUVAX-C19) and characterized its ability when formulated with a nanoemulsion adjuvant to induce anti-spike antibody and T-cell responses and provide protection including against viral transmission in rodent.	naruvax-c19	57-68	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	27-32	
35197485-2	2022	We developed a recombinant spike protein vaccine (called NARUVAX-C19) and characterized its ability when formulated with a nanoemulsion adjuvant to induce anti-spike antibody and T-cell responses and provide protection including against viral transmission in rodent.	naruvax-c19	57-68	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	160-165